Reims

• Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on inci … Recruiting
  2024-515075-36-00 6 2021-12-01 kidney transplantion -Epstein Barr virus
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre … Recruiting
  2024-517215-67-00 5 2021-06-11 Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
• Comparison of Cyclophosphamide and doxorubicin as a first line treatment in elderly patients with metastatic sarcoma Recruiting
  2024-510653-10-00 5 2021-06-04 Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting
  2024-514025-30-00 4 2021-03-25 Ocular conservative treatment for retinoblastoma
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri … Recruiting
  2024-516649-38-00 5 2020-12-01 Recurrent ovarian, fallopian tube or primary peritoneal cancer
• Interest of peri operative CHemotherapy In patients with CINSARC highrisk localized Soft Tissue Sarcoma. Recruiting
  2024-515384-62-00 5 2020-10-09 Soft Tissue Sarcoma
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for … Recruiting
  2024-511904-18-00 10 2020-07-08 Pancreatic adenocarcinoma (PAC)
• Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine ad … Recruiting
  2024-514603-34-00 5 2020-03-02 intermediate-risk differentiated thyroid cancer patients
• International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica … Recruiting
  2022-501454-11-00 5 2020-02-05 standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting
  2023-508072-11-00 5 2019-06-26 Castration-resistant prostate cancer
• Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g … Recruiting
  2024-512629-97-00 4 2019-01-23 Patients with locally advanced or metastatic low grade endometrial str
• Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r … Recruiting
  2024-514780-26-00 4 2018-10-23 Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
• Conservative treatment of patients with retinoblastoma Recruiting
  2024-517275-21-00 4 2012-02-20 Retinoblastoma
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab … Ended recruitment
  2024-511650-50-00 5 2025-01-17 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended recruitment
  2024-518669-83-00 4 2024-12-05 acute promyelocytic leukemia (APL) in children and adolescents
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)

Showing 121–144 of 208 trials